IGM Biosciences Inc at Stifel Virtual Healthcare Conference Transcript
All right. Good afternoon. I'm Stephen Willey, one of the Senior Biotech Analysts here at Stifel. I'm glad to have with us here today from IGM Biosciences, CEO, Fred Schwarzer. We're just going to have kind of an informal discussion about some of the most relevant topics right now, ASH being obviously one of them.
I think there is kind of a portal that is available, if you have any kind of pressing questions, you can enter them into the portal, and we'll try to get them asked and answered as appropriate. But Fred, thanks for joining us today. I don't know if you want to make any kind of introductory comments at all before we jump into Q&A at all?
Well, other than to say thank you very much. It's always a pleasure to talk with you, and we always enjoy our conversations. And why don't we just dive in because we're very excited about our ASH abstract data. I'm sure you've got to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |